RT Journal Article
T1 Cutaneous leishmaniasis associated with TNF-α blockers: a case report.
A1 Nieto Gómez, Pelayo
A1 Casas Hidalgo, Inmaculada
A1 Casas Hidalgo, María de la Paz
A1 Álvarez Sánchez, Raquel
A1 Rodríguez Delgado, Alejandro
A1 Cabeza-Barrera, Jose
K1 anti-tnf
K1 immunosuppression
K1 infliximab
K1 leishmaniasis
K1 psoriatic arthritis
AB Leishmaniasis is a chronic protozoan disease that is found in diverse geographical areas of the world. Leishmania spp. are endemic in the Mediterranean coasts of southern Europe. Tumour necrosis factor alpha (TNF-α) plays an important role in the defence of the host against infection by Leishmania spp. In this case report we describe Leishmania infection caused by a monoclonal antibody against TNF-α: infliximab. A 51-year-old patient with psoriatic arthritis treated with infliximab, 5 mg/kg every 6 weeks as immunomodulatory treatment and methotrexate 10 mg weekly as a conventional disease-modifying antirheumatic drug, visited his otorhinolaryngologist owing to a lesion in his left nostril. The lesion was diagnosed as cutaneous leishmaniasis so treatment with infliximab was suspended. The patient was then treated with liposomal amphotericin B and showed a total recovery of the lesion; liposomal amphotericin B was maintained at 5 mg/kg monthly.
SN 2047-9956
YR 2018
FD 2018-05-05
LK http://hdl.handle.net/10668/14297
UL http://hdl.handle.net/10668/14297
LA en
DS RISalud
RD Apr 6, 2025